Latest / "Isn't That Interesting?!": Breast Cancer Survivor Stories + Remarkable Research / Season 3 / Episode 10: Dr. Marie Lee
Transcript
- 0:00When trial meets error, it's often a step forward, not a step
- 0:03back. Thanks to scientists,
- 0:05researchers and physicians, Perseverance, hope, and of
- 0:09course, funding continue to move us closer to the.
- 0:12Goal of earlier. Cancer Detection 1 researcher
- 0:15helping use that effort is Doctor Marie Lee of the Mafia
- 0:18Cancer Center in Tampa, FL. Her work is bringing new
- 0:22insights to the fight against those at high risk for breast
- 0:25cancer and helping pave the way for future breakthroughs.
- 0:29Here's our founder and executive director, Martha Kaley with this
- 0:32episode of Isn't That Interesting?
- 0:37Well, hello everybody, and I want to introduce you to Doctor
- 0:41Catherine Lee. She is one of our researchers
- 0:45that that we've granted a a grant to and 29 20 2020 2009 and
- 0:54I'm going to just chat with her. She's been doing a lot of work
- 0:58and I'm really excited to understand what else she's
- 1:00doing. But the grade that we funded her
- 1:02was identifying circulating serum, serum biomarkers via gene
- 1:08expression profiling for breast cancer screening.
- 1:12And as I've been studying, there seems like that this is a really
- 1:17hot topic. So Doctor Lee, I'm going to just
- 1:21let you discuss what your findings were and and being sort
- 1:27of an initial grant, yeah, where it LED you.
- 1:29So I'm gonna just let you go ahead and give us some direction
- 1:32about what your research was about.
- 1:34Well, thank you so much. You know, I was actually really
- 1:37excited to talk about this because 2009, when when I
- 1:42received the funding was my, you know, sort of very early in my
- 1:47career. I had been, I had been a, an
- 1:49attending faculty surgeon for a little over a year at Moffett,
- 1:53which, which is where I'm still practicing.
- 1:55And that grant in many ways helped to establish my my career
- 2:01and my reputation as a translational breast cancer
- 2:05researcher. Not a lot of surgeons actually
- 2:08have the opportunity to do these things.
- 2:11And so even small seed grant funding like what I received
- 2:15actually served as a catalyst. So I'm so grateful to the
- 2:19organization for sort of starting off what I would
- 2:24consider kind of a domino effect over the subsequent however many
- 2:27years that I've been here in in developing an independent
- 2:31research program because I still practice as a surgeon and still
- 2:36spend most of my time doing breast cancer surgery.
- 2:39That particular project was really looking at serum from
- 2:44which is derived from whole blood.
- 2:47And we were looking for pretty hard to detect RNA markers
- 2:52within that serum that we might be able to use to detect breast
- 2:57cancer at it before it could be detected on a mammogram or in
- 3:02women that had breast cancer and that might be at a higher risk
- 3:05to have it show up somewhere else.
- 3:07I will say that the science was probably probably more advanced
- 3:11than what the technology could accommodate at that time, right?
- 3:15And the markers that we were looking for are ones that
- 3:19degrade very quickly. And so I think maybe now do we
- 3:24have laboratory techniques that now can preserve those markers
- 3:30in a better fashion than what we had?
- 3:32Oh, yeah. Now we're talking about 2009.
- 3:35My math, this is not very good, but that was a long time ago,
- 3:40yes. And so we've moved, we've moved,
- 3:43we've moved on to look, to look at other ways to detect risk and
- 3:51risk for cancer to show up somewhere else.
- 3:54And you know, the original interest on my part was really
- 3:58risk to develop cancer. And I, my focus has shifted to
- 4:02some degree because we know now that some breast cancer is what
- 4:07we would consider relatively lower risk to come back or to be
- 4:12a lifelong problem. And we know that there are some
- 4:15that are very high risk, right? We're worried about women dying
- 4:19from breast cancer because it comes back or it shows up
- 4:21somewhere else. And so a lot of the research
- 4:25techniques that we've been that that we've been working on, that
- 4:29we've developed over the years, we the focus is not necessarily
- 4:33so much in terms of detection, but actually trying to identify
- 4:39the women for whom that risk of cancer back can be detected.
- 4:44And I would say that probably on the commercial side when we look
- 4:49at laboratory testing that's being developed, that's also
- 4:52where the focus has been driven. We have actually over the past
- 4:56few years some very interesting work where patients have very
- 5:01generously agreed to allow us to take a bone marrow sample when
- 5:05I'm doing surgery on them. And in that we actually started
- 5:10by doing these, taking these samples from women that had
- 5:15breast cancer at all stages undergoing breast cancer
- 5:18surgery. And from that bone marrow, we
- 5:22are actually processing the cells and sorting them out and
- 5:26trying to identify a population of cells that we think might be
- 5:31precursors or indicators of future cancer risk, right, of
- 5:36breast cancer cutting. And this is not a new idea.
- 5:39There were trials that were run in the late in the 80s and into
- 5:44the 90s where bone marrow aspiration was also done to try
- 5:48to replicate this. But the techniques and the
- 5:51cellular techniques have gotten so much better that we are now
- 5:54able to identify what we are fairly sure is a high risk
- 5:59population of cells with some consistency in these women.
- 6:03So then in the past year or so, we've been able, through the
- 6:07generosity of mostly donated research funds to now extend
- 6:14this bone marrow collection to women that are considered high
- 6:17risk for breast cancer. So we have women that have gene
- 6:22mutations that put them at a higher risk for breast cancer.
- 6:26We have women who are undergoing surgery for, you know, an
- 6:29abnormality in the breast that's not cancer.
- 6:31But you know, we have a concern. And so we, we are now
- 6:35approaching those women to give bone marrow samples.
- 6:38And we are again looking for this, these populations of, of
- 6:42high risk cells in those bone marrow samples because we would
- 6:47love to somehow find a better way, right.
- 6:52And and so it's really these grants that your organization is
- 6:57giving out go way beyond the projects that they actually
- 7:02fund. And, and for someone like me,
- 7:06thank you. You guys like built my whole
- 7:07research career, or at least a lot.
- 7:09For us, right? Because yeah, because it the
- 7:13project itself as I said is was probably premature with regards
- 7:17to the technology that we have. But the lessons that we learned
- 7:21from from doing that, that small study have really built a lot
- 7:26and informed a lot of the decisions in the studies that I
- 7:29have designed and collaborated on in the subsequent 15 years.
- 7:34So thanks. For sure.
- 7:37Well, you know, one of the things I write down for myself
- 7:40is that this is called research. It's not called solving.
- 7:46So I feel like that if there's negative information, if
- 7:51something doesn't turn out right or turn out like it's expected,
- 7:56then we've learned another different thing.
- 7:59We've learned what not to do or we've learned how to modify what
- 8:03we're doing or investigate other things.
- 8:06And for like with your career, this is such an example of what
- 8:14my goal has always been is because if you don't have a
- 8:17chance to try something out, you just don't have any concept of
- 8:21what you can do. And I felt like that we were
- 8:24losing lots of great minds. Obviously, we're funded
- 8:29researchers all over the world and, and the young researchers,
- 8:34you got to start somewhere. So I just, that's where I'm, I
- 8:39think that we're fulfilling our need and what our goal is.
- 8:42And I'm, I'm consistently impressed with your the great
- 8:48that we funded. I had a question.
- 8:51So you were studying RNA, right? You were looking at RNA is, is,
- 8:56am I correct in thinking that that is a bit more challenging
- 9:01than DNA? And so, so I've wondered about
- 9:06the RNA. I read somewhere about that it
- 9:09impacted the DNA and it changed what the particular alteration
- 9:14was. It doesn't change the sequencing
- 9:16of the DNA, but it changes the action that what the action of
- 9:21the tumor like the being a tumor suppressor as opposed to not
- 9:26being a tumor suppressor. Can you guide me on that a
- 9:29little bit? Sure.
- 9:31So DNA is it's easy, it the easiest way to think about it is
- 9:35that DNA is a fixed resource, right?
- 9:38That's, that's the, the reference point for all of these
- 9:44nucleic acids, what we were doing in that well, and then RNA
- 9:49is a product of DNA. Basically RNA is trying to take
- 9:54a copy of some segment of the DNA and mRNA.
- 9:59Messenger RNA, which is what we were looking at, is trying to
- 10:02carry that message from DNA to the cell to carry out whatever
- 10:08process it is that that message is trying to instruct.
- 10:12So the DNA is your reference point and the mRNA is the
- 10:18messenger. So what we were really looking
- 10:20at in that study was mRNA in blood.
- 10:24The hard part about mRNA messenger RNA is it's not
- 10:29supposed to last forever, right? It's supposed to carry out a
- 10:32message to the cell and then go away, right?
- 10:35We don't want to confuse cells by giving them all these
- 10:39messages lingering around. Just like you're supposed to
- 10:41delete your emails when you're done with them, right?
- 10:43Say my let's do I get that right?
- 10:46Supposed to. So the what we were really
- 10:49looking for was alterations in mRNA, changes in the message
- 10:55that we're changing the behavior of the cells.
- 10:59Right. The hard part, of course, is
- 11:02that mRNA naturally degrades very quickly, too quickly for us
- 11:07to consistently get a signal. So sometimes we could find
- 11:12something that we, the thing that the section we were looking
- 11:15for, and sometimes we just couldn't.
- 11:18And some, a lot of it had to do with the fact that there's not a
- 11:21lot of mRNA overall, right? Because it's degrading.
- 11:25And then the ones that are preserved, once we started to
- 11:29process them would also start to degrade.
- 11:33And then the teeny tiny bits that we were left with weren't
- 11:37consistent enough for us to get a good read.
- 11:41Right. And of course, that's 2009 and
- 11:442010 and 2011 technology, which, at least in the world of Cancer
- 11:49Research, is like ancient history.
- 11:51Right, exactly. Yeah.
- 11:53And although I will say that even now, a lot of the work that
- 11:56we're doing and a lot of the sort of hot topic testing that's
- 12:00out there in terms of like blood testing is still actually
- 12:04looking at DNA that. So there are some commercially
- 12:07available tests that are looking for circulating DNA because the
- 12:12DNA holds up to a lot more. It's meant to.
- 12:16It's supposed to be the the reference library, so to speak.
- 12:19So and, and so there are a lot of approaches I think about
- 12:24circulating fragments of the DNA.
- 12:27Can you address that part? Yes, so that's what I was
- 12:31referring to. So you, you may or may not
- 12:33remember, gosh, it's probably been about 10 years ago now that
- 12:38it would, because it was, it was actually in the news that in, in
- 12:42pregnant women, they would find fragments of DNA or in women
- 12:48that have had a baby, they would find fragments of the DNA from
- 12:52the infant in the maternal blood, which was like a shocker.
- 13:00People aren't supposed to have somebody else's DNA, right?
- 13:03Right. And then in, so then somebody
- 13:08decided to start looking at this and they discovered that
- 13:12sometimes they could find fragments of DNA that actually
- 13:18suggested cancer, right. And so that has actually built
- 13:24this entire now and now commercially available testing
- 13:28where labs can look for fragments of DNA that are
- 13:33related to a tumor. Colon cancer and breast cancer
- 13:38is a little bit newer, but those are the cancers for which these
- 13:41blood tests are, are being, are really being looked at and used
- 13:46sort of in, in clinical practice to some degree.
- 13:49Because again, the DNA of the of the tumor is is preserved.
- 13:55They are not seeing the whole thing right.
- 13:58We're not finding tumor cells, but they're finding teeny tiny
- 14:01fragments and they're looking for teeny tiny fragments of
- 14:04residual cancer even after the cancer tumor has been removed.
- 14:10So for those tests, typically the lab needs a piece of
- 14:14somebody's original cancer so they can build the library,
- 14:20right? And then over time they draw
- 14:23that person's blood and check the blood for a piece of that
- 14:27tumor library within the the nucleic acids that are
- 14:32circulating in that person's blood.
- 14:34Those are very new tests. So what they how useful they
- 14:38will be, I think remains to be seen.
- 14:41Right, right. But it does build on the same
- 14:44ideas. Yes, well, I, I feel like that
- 14:49I've been amazed over the last 30 years about how the science
- 14:55has changed and it it seems that we are at a point in history
- 15:00that is explosive. How do you see AI supporting all
- 15:06of what what we're trying to achieve here?
- 15:08How do you see that working? Oh gosh.
- 15:12Now you really. Have about a few hours.
- 15:14You have today, you know, I think that we have to think of
- 15:19AI as a blessing and a curse, right?
- 15:22AI ultimately is are still computer algorithms.
- 15:26And so it's very dependent on what we give it.
- 15:29If we have good clean information that we can put into
- 15:33AI and we can ask it a specific question, I think we can get
- 15:37very useful information out of it, right.
- 15:40If you put a bunch of stuff in and ask AI to figure it out,
- 15:43you're gonna end up with a lot of really weird things.
- 15:46And then maybe 1 and a million, it's going to spit out some
- 15:51useful conjecture, right? I think we have to be very
- 15:54careful about what what we put into an AI algorithm.
- 16:00And then we have to be equally careful about the output that it
- 16:04gives us. I think that we have to really
- 16:06scrutinize even if we gave it the cleanest data and clean data
- 16:11is already, you know, kind of a relative term.
- 16:14Even if we give it the cleanest data, I think that we have to be
- 16:18careful to somehow validate, recheck the result that AI gives
- 16:23us because I'm not sure about the reliability.
- 16:26I I mean, is that, is that fair? If I give, if I gave an
- 16:30individual a bunch of jumbled stuff and said sort it out right
- 16:36and get the same result, But if I gave that same person, you
- 16:40know, a very discreet file that has these numbers and this
- 16:43calculation, then I would say we could probably rely on that
- 16:47person with their, you know, my 16 year old or my 13 year old
- 16:51with a calculator and a pen and paper, but I'm still going to
- 16:54check her work, right. The same idea.
- 16:56I think that that AI has incredible potential, but it's
- 17:00still a very early technology. And I think we we have to be, we
- 17:05still have to be very careful and, and prescribed when we're
- 17:11thinking about what we're putting into it.
- 17:14And we have to be even more careful about the result that it
- 17:17gives, because we don't necessarily know the algorithm
- 17:21that it uses by which it comes to to an answer.
- 17:26Right. Well, I feel like that that is
- 17:28so true for all of that. And, and because I feel like
- 17:31that we're just at the front end of, of what AI can, can do.
- 17:37And I feel like that it will just continue being improved and
- 17:41moving forward. So I just, it's a tool for us
- 17:47that can be very consequential, I think.
- 17:49And you're right. Is it either a blessing or a
- 17:52curse? And you know, it's, you got to
- 17:55look at from all different angles.
- 17:57Well, what is your particular focus now that you're working on
- 18:02as well as being a surgeon as well as being a mom?
- 18:05Is there anything else you've? Done.
- 18:06You know, the, the work that we're doing in the lab looking
- 18:11at bone marrow samples is it is very exciting and I hope that
- 18:15that we can continue to build on that work.
- 18:18We've really benefited from the generosity of people like
- 18:22yourself who are interested in, in furthering Cancer Research.
- 18:29You know, we don't always have or need $1,000,000 to do this
- 18:34stuff. It's really that that same
- 18:36concept of having a small idea that we can either build on or
- 18:42not. And hopefully this bone marrow
- 18:44research is actually at the stage where we can start to look
- 18:48bigger. The other, my other area of
- 18:51interest, something that I've been working on for a long time,
- 18:54probably about 15 years now, and I have some really brilliant
- 18:57collaborators here at Moffett who helped me with this because
- 19:01this is like way beyond a surgeon's purge is, is
- 19:05developing very specialized antibodies.
- 19:10They are not. They're so small that we call
- 19:12them nano bodies and we are trying to engineer them to
- 19:16identify cancer cells that have traveled to lymph nodes, right?
- 19:22Because one of the things that we do as surgeons and that we
- 19:25have tried to do over the past 10 or 15 years is to figure out
- 19:31for what patients can we do less surgery in the underarm.
- 19:35And there's a lot of ways now that we try to do less surgery,
- 19:40but none of them are actually very specific to the cancer.
- 19:44We're kind of estimating who has what, right.
- 19:47And So what we've been working on for quite a long time now is
- 19:51something that we can dye basically that we could try to
- 19:54inject into the patient. And then in surgery, hopefully
- 19:59give me like a visual indicator of this is what has to come out.
- 20:03And then if it gets good enough that at some point maybe we
- 20:07don't need to do surgery, we can put the patient on a scanner or,
- 20:11you know, use a detector to see if that dye ended up in lymph
- 20:15nodes or not. In which case, if it doesn't
- 20:18show up, then maybe that patient doesn't need an operation.
- 20:22And if at some point my career is gone because there's no more
- 20:25surgery for breast cancer, I'll be OK with that, yeah.
- 20:28Yeah, working work is a great idea.
- 20:32I would be OK with that. I would continue in Cancer
- 20:34Research and maybe I'd pick up dog training.
- 20:37Right, right. Let's see.
- 20:39There's, I don't know if you Doctor Sasha Stanton, she is in
- 20:45Washington and her work was involved with the an antibody
- 20:51panel which I found so fascinating.
- 20:55And I was thinking about is it how those antibodies demonstrate
- 21:02or how you link those to give a program, you know, like it's the
- 21:06these, these are the antibodies that I'm working on.
- 21:11She has some interesting information.
- 21:13And and so when you mentioned those antibodies that that just
- 21:17came to my mind for, for her work too.
- 21:20So I think it's it's, it's another approach and it's just a
- 21:24everything is so valuable. Well, is there anything else
- 21:28that you would like to say for for general, for the general
- 21:33public? I mean, of course earlier
- 21:35detection is our is definitely our goal and the easier the
- 21:40better. So, so your perspective is very
- 21:44helpful. Is there?
- 21:45What are you seeing for the to look ahead for?
- 21:48You know, as somebody who's whose primary job is still to
- 21:52treat women with breast abnormalities and mostly breast
- 21:56cancer, I would say that there's a lot of exciting work, right?
- 22:00We're doing a lot of really high level testing and, and a lot of
- 22:05trials, but at the end of the day, the best test is still to
- 22:09get a mammogram every year. It's not a perfect test, right?
- 22:15And, and so I know that there are people that are disappointed
- 22:18that their mammogram didn't show XY or Z, but it was never meant
- 22:21to be a perfect test. It's, it's meant to be a test
- 22:25that everyone who hopefully has access to and that can be
- 22:30interpreted by any radiologist. It's a basic of, of their
- 22:35training. Because even though it's not a
- 22:38perfect test, it's something that has a broad reach, just
- 22:42like breast cancer has a broad reach.
- 22:43So I would still encourage people to do their mammogram and
- 22:47maybe in 5 or 10 or 15 years we'll have something better.
- 22:51Right. You know, that's what a lot of
- 22:54people I hear say, well, that doctor didn't find my breast
- 22:58cancer. And my response to that is that
- 23:01doctor is doing the best he or she can, but it's our technology
- 23:06that we haven't provided for that doctor to be able to do
- 23:09that. So, you know, don't throw it all
- 23:11out the window because use what we have.
- 23:15It's the best that we've got, but that doesn't mean that we
- 23:18can't improve. That is, that is exactly right.
- 23:21We can't, we can't throw the baby out with the bath water.
- 23:24Mammograms have been a very useful test for 50 years at this
- 23:29point. And like I said, it's not
- 23:31perfect, but it is still when you look at a huge population of
- 23:36people, right where over 50% of the American population and less
- 23:41than 40% of women who should get an annual screening mammogram
- 23:44are getting them. We have a lot of room to do
- 23:47better even in that domain. Right.
- 23:50Well, thank you Doctor Lee. I have so enjoyed visiting with
- 23:54you and we will be sharing this in the future and we just
- 23:59appreciate your work and I so appreciate your having time to
- 24:02spend with me. Thank you.
- 24:03And and yet, now you have to get back to work, right?
- 24:06I do, but thank you so, so much. I, I am so appreciative to the
- 24:10organization for the work that you do and the effect that that
- 24:14you and your group had on, on my career.
- 24:16We I wouldn't be here without your contributions.
- 24:19To well, I'm glad that we were able to do that and I, I know
- 24:23all of our donors will be happy to hear that too.
- 24:26So thank you so much. Well, best of luck to you.
- 24:29Hopefully we'll talk again soon. OK.
- 24:31Thank you. My pleasure.
- 24:33This episode of Isn't That Interesting was made possible
- 24:36thanks to volunteers and donors just like you.
- 24:39It was hosted by Martha Kaley, founderofearlier.org and edited
- 24:43by Liam Mcburney. I'm Valerie Amsterdam, reminding
- 24:47you that for the last 30 years, this is North Carolina based
- 24:50organization has helped fund groundbreaking research all over
- 24:54the world, from molecular imaging to a sensitive blood
- 24:58test for breast cancer. Plain and simple, earlier
- 25:01detection saves lives. And you can help host a
- 25:04fundraising event, make a donation or volunteer your time.
- 25:08You can find us not only on the web, but on Facebook and
- 25:10Instagram too. Let's change the picture of
- 25:13breast cancer together.